How Much Does Liraglutide Cost in Utah in 2026?

Utah Retail and List Prices for Liraglutide in 2026

The manufacturer list price for liraglutide (branded as Saxenda for obesity or Victoza for type 2 diabetes) from Novo Nordisk sits at $1,349 per month as of 2026. That figure rarely reflects what patients actually pay, but it sets the ceiling for uninsured buyers.

Across Utah retail pharmacies, the average cash-pay price lands around $900 per month for the 6 mg/mL, 3 mL prefilled pen used at maintenance dosing (3.0 mg daily for weight management). Prices vary by pharmacy location and purchasing agreements. Salt Lake City metro pharmacies occasionally price below $850, while rural pharmacies in southern Utah may charge closer to $950 or more due to lower volume purchasing power.

Liraglutide was first approved by the FDA in 2010 for type 2 diabetes under the brand Victoza, then in 2014 at higher doses for chronic weight management as Saxenda. The SCALE Obesity and Prediabetes trial (N=3,731) demonstrated that liraglutide 3.0 mg daily produced 8.0% mean body weight reduction versus 2.6% with placebo at 56 weeks. That trial also showed 63.2% of liraglutide-treated participants achieved at least 5% body weight loss, compared to 27.1% on placebo [1].

For a Utah resident paying cash, the annual cost at retail averages $10,800. That number makes alternatives worth serious consideration.

Compounded Liraglutide in Utah: Legality, Cost, and Access

Compounded liraglutide is legal in Utah through licensed 503A pharmacies. This is the single biggest cost lever available to Utah patients right now.

Under federal law, Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed compounding pharmacies to prepare patient-specific medications when a valid prescription exists and the drug is not essentially a copy of a commercially available product in shortage. Utah's Division of Occupational and Professional Licensing (DOPL) regulates these pharmacies under Utah Code Title 58, Chapter 17b. The cost for compounded liraglutide from a 503A pharmacy in Utah averages approximately $150 per month, roughly 83% less than the average retail cash price and 89% below list price.

A few practical details matter. The compounded product is not FDA-approved as a finished dosage form. It must be prescribed by a licensed provider to a specific patient. The pharmacy must hold a valid Utah compounding license. Patients should verify that their compounding pharmacy uses third-party potency and sterility testing, because the FDA has issued multiple warning letters to compounders failing quality standards.

At $150 per month versus $900, compounded liraglutide saves a Utah patient approximately $9,000 annually. For patients without insurance coverage, this price difference determines whether treatment is financially sustainable past the first month.

Utah Medicaid and Liraglutide: Current Coverage Status

Utah Medicaid does not cover liraglutide for chronic weight management as of 2026. This applies to both traditional Medicaid and the expanded Medicaid population that Utah enrolled starting in 2020.

The exclusion follows a pattern seen across many state Medicaid programs. The Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity recommends anti-obesity medications as adjuncts to lifestyle modification for patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with weight-related comorbidities, but Medicaid formulary decisions are made state by state. Utah's Medicaid Drug Utilization Review Board has consistently excluded anti-obesity agents from the preferred drug list.

For type 2 diabetes, coverage is handled differently. Victoza (liraglutide 1.8 mg) may receive prior authorization approval under Utah Medicaid for type 2 diabetes management when metformin alone is insufficient, but the weight-management indication at the 3.0 mg dose remains excluded.

Patients on Utah Medicaid who need weight-management pharmacotherapy have limited formulary options. Some may qualify for patient assistance programs or compounded alternatives, which are discussed below. The Utah Department of Health and Human Services reviews its formulary annually, but no public signals suggest liraglutide coverage for obesity is under active consideration for the 2026-2027 benefit year.

Insurance Coverage for Liraglutide Across Utah Commercial Plans

Commercial insurance coverage for liraglutide in Utah is inconsistent. Most major carriers require prior authorization, step therapy, or both before approving the drug.

SelectHealth, the dominant regional insurer affiliated with Intermountain Health, covers Victoza for type 2 diabetes but requires prior authorization for Saxenda. Criteria typically include documented BMI ≥30 kg/m² (or ≥27 kg/m² with at least one weight-related comorbidity), failure of a structured lifestyle intervention lasting 6 months, and no concurrent use of other GLP-1 receptor agonists. The American Association of Clinical Endocrinology (AACE) 2016 consensus statement on obesity supports pharmacotherapy as part of a comprehensive treatment algorithm, and most insurers reference these or similar guidelines for prior authorization criteria.

Blue Cross Blue Shield of Utah, Regence, and Molina each maintain their own formulary rules. Coverage denials are common for first-time requests when documentation is incomplete. Dr. Caroline Apovian, then at Boston University School of Medicine, stated in the context of the SCALE trial results: "The magnitude of weight loss with liraglutide 3.0 mg, combined with improvements in cardiometabolic risk factors, supports its role as a meaningful addition to obesity treatment" [1].

Employer-sponsored self-funded plans, which cover a large share of Utah's commercially insured population, vary even more widely. Some explicitly carve out anti-obesity medications. Others defer to their pharmacy benefit manager's standard formulary. Patients should request a formulary exception letter from their prescriber and confirm whether their plan classifies obesity treatment as a medical benefit or a pharmacy benefit, because appeal pathways differ.

A 2021 analysis published in Obesity found that only 11% of employer-sponsored plans covered all FDA-approved anti-obesity medications without restrictions. That figure has improved modestly since GLP-1 agonists gained broader clinical traction, but gaps remain.

Savings Cards and Discount Programs Available in Utah

Novo Nordisk offers a manufacturer savings card for Saxenda that can reduce out-of-pocket costs for commercially insured patients. The card is not available to patients on government insurance (Medicaid, Medicare, Tricare, or VA).

For eligible patients, the savings card may reduce copays to as low as $25 per month for up to 12 months, depending on plan structure and the specific offer terms active at the time of enrollment. Patients must re-enroll annually. The program is administered through Novo Nordisk's patient assistance portal, and eligibility can be verified at enrollment.

Beyond manufacturer programs, Utah patients have several additional avenues. GoodRx and RxSaver aggregate pharmacy pricing and occasionally surface coupons that bring retail prices below $800 per month at specific Utah locations. The NeedyMeds database tracks patient assistance programs for liraglutide and related GLP-1 drugs. The CDC's National Diabetes Prevention Program operates recognized sites in Utah that may help patients qualify for coverage by documenting structured lifestyle intervention attempts, which insurers require before authorizing anti-obesity medications.

Stacking strategies matter. A patient with commercial insurance, a manufacturer savings card, and documentation of prior lifestyle intervention attempts has the strongest position for minimizing cost. A patient without insurance should evaluate compounded liraglutide first, then explore manufacturer patient assistance as a secondary option.

Telehealth Prescribing of Liraglutide in Utah

Telehealth prescribing of liraglutide is legal in Utah. This is true for both the Saxenda (weight management) and Victoza (diabetes) indications.

Utah adopted permanent telehealth practice standards under Utah Administrative Code R156-1-602, which allow licensed prescribers to establish a valid prescriber-patient relationship via synchronous audiovisual technology. No in-person visit is required before writing a prescription for liraglutide, provided the telehealth encounter meets the standard of care.

For Utah residents outside the Wasatch Front, telehealth eliminates the 1-3 hour drive to an obesity medicine specialist that patients in rural counties like Carbon, Emery, or San Juan might otherwise face. The prescriber must hold an active Utah medical license or a relevant interstate compact license. Multiple national telehealth platforms now serve Utah patients with GLP-1 prescribing programs, including platforms that coordinate directly with compounding pharmacies to fill prescriptions at lower cost.

The Endocrine Society has noted that ongoing monitoring during anti-obesity pharmacotherapy should include regular assessment of weight trajectory, side effects, and metabolic parameters. Telehealth follow-ups at 4-week intervals during dose titration and quarterly thereafter satisfy this requirement for most patients.

How Liraglutide Compares to Other GLP-1 Options on Cost in Utah

Liraglutide is not the only GLP-1 receptor agonist available to Utah patients, and cost comparisons shape prescribing decisions.

Semaglutide 2.4 mg weekly (Wegovy) lists at approximately $1,349 per month, similar to Saxenda. However, the STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo, nearly double the efficacy of liraglutide 3.0 mg in the SCALE trial [2]. Tirzepatide (Zepbound) showed even greater weight reduction in the SURMOUNT-1 trial (N=2,539), with the 15 mg dose producing 22.5% mean weight loss at 72 weeks [3].

On a pure cost-per-pound-lost basis, semaglutide and tirzepatide outperform liraglutide at equivalent retail prices. But that calculation changes when compounding enters the picture. Compounded liraglutide at $150 per month is significantly cheaper than compounded semaglutide, which typically runs $250-400 per month from Utah 503A pharmacies. The weekly injection schedule of semaglutide also differs from liraglutide's daily dosing. Some patients prefer daily dosing because it allows finer dose titration and faster washout if side effects arise.

Dr. Robert Kushner, Professor of Medicine at Northwestern University Feinberg School of Medicine, has stated: "The choice among GLP-1 receptor agonists should consider not only efficacy differences but also patient preference for injection frequency, tolerability profile, and realistic out-of-pocket cost, because the best medication is the one the patient can afford to take consistently."

The American Gastroenterological Association's 2022 clinical practice guideline on pharmacological interventions for adults with obesity recommends semaglutide 2.4 mg as first-line pharmacotherapy for obesity, with liraglutide 3.0 mg as an alternative [4]. In Utah's current pricing environment, liraglutide's compounded cost advantage may make it the more practical first-line choice for uninsured or underinsured patients.

Dose Titration and Monthly Supply Costs During Ramp-Up

Liraglutide requires a 4-week dose titration before reaching the maintenance dose, which affects the first month's cost and pen usage.

The FDA-approved titration schedule for the 3.0 mg weight-management dose is: 0.6 mg daily for week 1, 1.2 mg for week 2, 1.8 mg for week 3, 2.4 mg for week 4, then 3.0 mg daily thereafter. During the titration month, total drug consumption is lower than at maintenance. A patient using the standard 6 mg/mL, 3 mL pen (18 mg total per pen) will use fewer pens during titration than during a full maintenance month.

At retail, pharmacies typically dispense a 30-day supply regardless of titration status, so the cost difference may not appear on the receipt. With compounded liraglutide, some 503A pharmacies offer a reduced first-month price or a titration-specific vial with lower total volume. Patients should ask.

Gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) are the primary reason for slow titration. In SCALE, nausea occurred in 40.2% of liraglutide-treated participants versus 14.7% on placebo, but most cases were mild to moderate and resolved within the first 4-8 weeks [1]. Skipping the titration to save money on a shorter supply is not recommended; it increases the risk of intolerable GI symptoms that lead to discontinuation.

What Utah Patients Should Do Next

Start by determining your insurance status and checking your formulary for liraglutide or Saxenda coverage. If covered, request prior authorization documentation from your prescriber. If denied or uninsured, get a prescription filled through a licensed Utah 503A compounding pharmacy at approximately $150 per month. Verify the pharmacy's sterility testing records before filling. For telehealth access, confirm your provider holds an active Utah prescribing license, and schedule follow-ups every 4 weeks during titration. The maintenance dose is 3.0 mg subcutaneously once daily.